Glenmark Pharmaceuticals had on Friday received manufacturing and marketing
approval from India’s drug regulator, making FabiFlu the first oral
Favipiravir-approved medication in India for the treatment of COVID-19.
approval from India’s drug regulator, making FabiFlu the first oral
Favipiravir-approved medication in India for the treatment of COVID-19.
FabiFlu will be used for treating COVID-19 patients with mild to moderate
symptoms and will be made available from today evening and by next week across
the country. The company has got approval under emergency category.
symptoms and will be made available from today evening and by next week across
the country. The company has got approval under emergency category.
మొదటి రోజు, ఒక రోగికి 1800 మి.గ్రా చొప్పున రెండుసార్లు ఇవ్వబడుతుంది. రెండవ రోజు నుండి, వైద్యుడి సలహా ప్రకారం రోగికి 14 రోజుల వరకు రోజుకు రెండుసార్లు 800 మి.గ్రా ఇవ్వబడుతుంది. 18 నుండి 75 సంవత్సరాల మధ్య వయస్సు ఉన్న రోగులకు ఈ medicine ఇవ్వవచ్చు
Each tablet of 200 mg costs ₹103 and a strip containing 34 tablets has been
priced at ₹3500. It will be made available at hospitals and chemist shops and
will be sold under medical presciption.
priced at ₹3500. It will be made available at hospitals and chemist shops and
will be sold under medical presciption.
Since the approval is under emergency category due to the pandemic, the
patient has to give an undertaking before consuming the medicine.
patient has to give an undertaking before consuming the medicine.
70 to 80% of Covid-19 patients are from the mild and medium category for
which the drug has been approved. A patient of this type need not be
admitted to the hospital and can stay at home.
which the drug has been approved. A patient of this type need not be
admitted to the hospital and can stay at home.
Glenmark is taking care of end to end processes of this medication starting
from manufacturing API and development of formulation to manufacturing as
well as marketing and supply. Company executives said this will help in
reducing the pressure on hospitals.
from manufacturing API and development of formulation to manufacturing as
well as marketing and supply. Company executives said this will help in
reducing the pressure on hospitals.
Clinical trial is on for 150 patients in India. For the next stage, the
company is planning for a combination trial for Covid-19 treatment.
company is planning for a combination trial for Covid-19 treatment.
Once administered the drug will help in bringing down the viral load on the
patient, company executives said.
patient, company executives said.
Glenmark is the first company to come out with an oral antiviral drug for
mild and moderate Covid-19 treatment.
mild and moderate Covid-19 treatment.
Favipiravir has been used in Russia, Japan and China to treat such patients
and has been proved successful.
and has been proved successful.
At the moment the drug will be under restricted use, which means it can be
consumed only under doctor’s guidance and supervision. People without
prescription cannot buy it.
consumed only under doctor’s guidance and supervision. People without
prescription cannot buy it.
